Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: An Italian perspective by Rapezzi, Claudio et al.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CLINICAL RESEARCH
Heart failure/cardiomyopathy
Disease profile and differential diagnosis
of hereditary transthyretin-related amyloidosis
with exclusively cardiac phenotype: an
Italian perspective
Claudio Rapezzi1*, Candida Cristina Quarta1, Laura Obici2, Federico Perfetto3,
Simone Longhi1, Fabrizio Salvi4, Elena Biagini1, Massimiliano Lorenzini1,
Francesco Grigioni1, Ornella Leone5, Francesco Cappelli3, Giovanni Palladini2,
Paola Rimessi6, Alessandra Ferlini6, Giorgio Arpesella7, Antonio Daniele Pinna8,
Giampaolo Merlini2, and Stefano Perlini2
1Cardiovascular Department, University of Bologna and S. Orsola-Malpighi Hospital, via Massarenti 9, 40138 Bologna, Italy; 2Center for Amyloidosis, ‘Fondazione IRCCS San Matteo’
and University of Pavia, Pavia, Italy; 3Regional Amyloid Center, Azienda Ospedaliera Universitaria Careggi, Florence, Italy; 4Department of Neurology, Bellaria Hospital, Bologna, Italy;
5Department of Pathology, University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; 6Section of Medical Genetics, Department of Diagnostic and Experimental Medicine,
University of Ferrara, Ferrara, Italy; 7Department of Cardiac Surgery, University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; and 8Department of Surgery and
Transplantation, Liver and Multiorgan Transplant Unit, University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy
Received 9 January 2012; revised 4 April 2012; accepted 17 April 2012; online publish-ahead-of-print 28 June 2012
See page 483 for the editorial comment on this article (doi:10.1093/eurheartj/ehs238)
Aims Hereditary transthyretin (TTR)-related amyloidosis (ATTR) is mainly considered a neurologic disease. We assessed
the phenotypic and genotypic spectra of ATTR in a Caucasian area and evaluated the prevalence, genetic background,
and disease profile of cases with an exclusively cardiac phenotype, highlighting possible hints for the differential
diagnosis with hypertrophic cardiomyopathy (HCM) and senile systemic amyloidosis (SSA).
Methods
and results
In this Italian multicentre study, 186 patients with ATTR were characterized at presentation. Thirty patients with SSA
and 30 age–gender-matched HCM patients were used for comparison. Phenotype was classified as exclusively
cardiac (n ¼ 31, 17%), exclusively neurologic (n ¼ 46, 25%), and mixed cardiac/neurologic (n ¼ 109, 58%). Among
the eight different mutations responsible for an exclusively cardiac phenotype, Ile68Leu was the most frequent.
Five patients with an exclusively cardiac phenotype developed mild abnormalities at neurological examination, but
no symptoms during a 36-month follow-up (range: 14–50). Exclusively cardiac phenotype was characterized by
male gender, age .65 years, heart failure symptoms, symmetric left ventricular (LV) ‘hypertrophy’, and moderately
depressed LV ejection fraction. This profile was similar to SSA, but relatively distinct from HCM. Compared with
patients with a mixed phenotype, patients with an exclusively cardiac phenotype showed a more pronounced
cardiac involvement on both echocardiogram and electrocardiogram (ECG).
Conclusion A clinically relevant subset of Caucasian ATTR patients present with an exclusively cardiac phenotype, mimicking
HCM or SSA. Echocardiographic and ECG findings are useful to differentiate ATTR from HCM but not from SSA.
The role of liver transplantation in these patients should be reconsidered.
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Introduction
Hereditary transthyretin-related amyloidosis (ATTR, also referred
to as familial amyloidotic polyneuropathy) is characterized by the
extracellular deposition of amyloid fibrils formed by the transport
protein transthyretin (TTR), which is produced by the liver.1 ATTR
is caused by over 100 amyloidogenic TTR gene mutations and is
the most common form of familial amyloidosis.1 Its clinical spec-
trum varies widely from an exclusively neurological involvement
to a predominantly cardiac presentation. This heterogeneity is
linked to several factors including specific TTR mutations, patient
and transmitting parent gender, geographical distribution, and
endemic/non-endemic aggregation.2 –6 While the clinical features
and natural history of ATTR associated with the Val30Met muta-
tion have been widely studied,2 –5 the disease profile of the
forms with an exclusively/predominantly cardiac involvement
[also referred to as familial amyloidotic cardiomyopathy (FAC)]
has been defined far less, and knowledge derives mainly from
studies focusing on single mutations in different geographical con-
texts,7,8 often limited to a single kindred.9,10 In particular, at least
four different mutations have been shown to be responsible for
an exclusively or predominantly cardiac phenotype: Val122Ile,
Thr60Ala, Leu111Met, and Ile68Leu.7 – 10 FAC is probably widely
underdiagnosed, mainly because the disease can mimic other
causes of left ventricular (LV) hypertrophy, including hypertensive
heart disease, hypertrophic cardiomyopathy (HCM), and the non-
mutant form of ATTR [senile systemic amyloidosis (SSA)].11,12
Since our centres attract patients from a nationwide territory,
the aim of this study was to assess the phenotypic and genotypic
spectra of ATTR in a Caucasian area and, in particular, to evaluate
the prevalence, genetic background, and disease profile at presen-
tation of cases with an exclusively cardiac phenotype, highlighting
possible hints for the differential diagnosis with HCM and SSA.
Patients and methods
Clinical setting and study design
Cross-sectional analysis
We conducted a cross-sectional, multicentre study of patients with
ATTR at the time of diagnosis. The setting was the three main Italian
referral centres for the diagnosis and treatment of hereditary amyloid-
osis (Bologna, Pavia, and Florence), all providing coordinated amyloid-
osis networks involving neurology, cardiology, haematology, and
nephrology services, genetic research groups, and liver/heart trans-
plantation programmes. Data on genotyping and a comprehensive
set of cardiac, neurologic, and other relevant clinical/instrumental
examinations were routinely collected according to an institutional
protocol for all patients and stored in a dedicated database. All patients
observed by our network at the time of definitive diagnosis of ATTR,
between 1990 and December 2010, were eligible for the present
study, including those identified through family screening who
displayed clinical/instrumental evidence of disease.
Phenotype at baseline (i.e. at the time of first evaluation) was classi-
fied as: (i) ‘cardiac phenotype’, based on echocardiographic and/or
electrocardiographic (ECG) evidence of cardiac amyloidosis in the
absence of any sign or symptom of neurological involvement; (ii)
‘neurologic phenotype’, based on clinical/instrumental evidence of
neuropathy in the absence of any echocardiographic, ECG, or clinical
evidence of amyloidotic cardiomyopathy; and (iii) ‘mixed (cardiac/
neurologic) phenotype’.
We compared clinical and instrumental (ECG and echocardiograph-
ic) characteristics at baseline of patients with cardiac phenotype with
those of patients with mixed phenotype. Baseline profiles of patients
with a cardiac phenotype were also compared with those of patients
diagnosed with SSA during the same time period and with those of
30 age- and gender-matched patients with genetically proven
sarcomeric HCM.
Longitudinal analysis
For patients with a cardiac phenotype at the time of first evaluation, we
assessed the natural history of the disease in terms of development of
clinical/instrumental signs of neurological involvement. Follow-up of
these patients was closed in September 2011.
All study participants provided informed consent for DNA analysis,
any routine invasive procedures, and anonymous data publication. Ap-
plication for formal approval by a local institutional Ethics Committee
was not applicable for this retrospective observational study.
Diagnostic definitions and patients’
assessment
For the diagnosis of systemic amyloidosis,11 of familial ATTR,13 and of
SSA,14 as well as for the definition of cardiac involvement,15–17 of
peripheral nervous system involvement,1,18,19 and of autonomic neur-
opathy,15,18 we referred to the standard diagnostic criteria. A detailed
list of diagnostic definitions is found in the Supplementary material
online.
In all patients, cardiac investigations included accurate search for
signs and symptoms of heart failure, standard ECG,20 and transthoracic
echocardiography.21 A description of ECG and echocardiographic
definitions and analysed variables is reported in the Supplementary
material online.22,23
Genotyping
Genomic DNA was isolated from whole peripheral blood by standard
techniques. Exons 2, 3, and 4 of the TTR gene (accession number
m11844) were amplified by polymerase chain reaction (Takara
ExTaq polymerase) using primers described previously.13 Amplified
DNA fragments were directly sequenced using an ABI Prism 3130
automated sequencer.
Statistical analysis
Summary statistics were expressed as median (interquartile range) or
numbers (percentages). In contingency tables, independence of cat-
egorical variables was tested using Fisher’s exact test or Pearson’s x2
test. Independence of continuous variables was tested using Mann–
Whitney U test/Kruskal–Wallis test. For multiple comparisons, we cal-
culated Bonferroni-adjusted P-values. Analyses were conducted using
STATA 11.2 SE. All tests were two-sided; P-values less than 0.05
were considered significant.
Results
Study population
A total of 186 patients diagnosed with ATTR at our centres in
1990–2010 were included in the study. All patients were Cauca-
sian and belonged to 89 distinct families originating from southern,
central, and northern parts of Italy and were all of Italian descent,
with the exception of one patient (carrying Phe33Val mutation)
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who came from the Republic of Macedonia. Table 1 shows the
complete list of the 26 different TTR mutations identified in the
study population (families and patients): Val30Met was the most
frequent followed by Glu89Gln and Ile68Leu. All patients were
heterozygous for the identified mutation.
Baseline disease profile and genotype
At the time of diagnosis, 109 (58%) ATTR patients showed a mixed
phenotype, 46 (25%) a neurologic phenotype, and 31 (17%) a
cardiac phenotype. All patients with a cardiac phenotype displayed
both ECG and echocardiographic abnormalities, whereas among
those with a mixed phenotype, eight patients showed only ECG
abnormalities (left bundle branch block, n ¼ 1; right bundle
branch block, n ¼ 2; and left anterior hemiblock, n ¼ 5) without
any echocardiographic sign of amyloid infiltration: five of these
eight cases carried the Val30Met mutation. Indeed, all the patients
with cardiac phenotype and 101/109 (93%) of those with mixed
phenotype also showed morphological findings, suggesting infiltra-
tive myocardial disease including granular sparkling appearance of
ventricular myocardium, increased thickness of atrioventricular
valves or interatrial septum, and pericardial effusion.
Endomyocardial biopsy was performed in 66 patients with
cardiac involvement, confirming the presence of amyloid infiltra-
tion in all cases. The main baseline clinical characteristics of the
overall study population and according to the phenotype classifica-
tion are summarized in Table 2. Regarding the distribution of the
different TTR mutations in the different phenotype groups, not
only each phenotype was found to be associated with more than
one mutation, but also several mutations (including Val30Met,
Ile68Leu, and Glu89Gln) were associated with more than one
phenotype (Table 2).
Among the 31 patients with a cardiac phenotype, 15 (48%) had
previously received a misdiagnosis (HCM, n ¼ 7; dilated cardiomy-
opathy, n ¼ 2; hypertensive heart disease, n ¼ 3; chronic ischaemic
heart disease, n ¼ 2; and immunoglobulin light-chain (AL) amyloid-
osis, n ¼ 1). In all these cases, the suspicion of cardiac amyloidosis
emerged from a combined interpretation of clinical, echocardio-
graphic, and ECG findings: an ‘unexplained’ LV hypertrophy at
echocardiogram in the absence of LV hypertrophy on ECG was
the main trigger for the correct suspicion.
ECG and echocardiographic characteristics of the two pheno-
types with cardiac involvement are summarized in the Supplemen-
tary material online.
Follow-up of patients with a cardiac
phenotype
During a median follow-up of 36 (14–50) months, four patients
underwent combined heart– liver transplantation. One of these
patients also underwent kidney transplantation for a coexistent
non-amyloid-related chronic renal failure (previous acute glomer-
ulonephritis). Five of the 31 cases with an exclusively cardiac
phenotype developed abnormalities at neurological examination
during the follow-up period, suggesting mild sensitive neuropathy
(altered pain/temperature perception in the lower or upper
limbs without any motor impairment). These signs were exclusive-
ly evident at neurological evaluation and were not associated with
spontaneously reported symptoms.
Hereditary transthyretin-related
amyloidosis vs. senile systemic
amyloidosis and hypertrophic
cardiomyopathy
During the study period (1990–2010), 30 patients were diagnosed
with SSA. Thirty patients with genetically proven sarcomeric HCM
(age- and gender-matched) were also included in the study for
comparison. Sarcomere protein mutations included: MYBPC3 in
19 patients, TNNT2 in 6, and MYH7 in 4; a double MYH7/
TNNI3 mutation was present in a single case. Figure 1 and
Tables 3 and 4 report the main clinical, ECG, and echocardiograph-
ic findings of ATTR patients with cardiac phenotype and of SSA
and HCM patients.
Discussion
Our study shows that, in a Caucasian population of patients origin-
ating from an ATTR non-endemic geographical area, .15% of
cases at first evaluation have an exclusively cardiac phenotype.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Transthyretin-related amyloidosis mutations
in the study population according to families and
patients
Mutations Families, n (%) Patients, n (%)
Val30Met 20 (22.5) 46 (24.8)
Glu89Gln 9 (10.2) 40 (21.5)
Ile68Leu 22 (24.7) 27 (14.6)
Phe64Leu 10 (11.2) 13 (7)
Thr49Ala 1 (1.1) 12 (6.5)
Gly47Ala 2 (2.3) 7 (3.8)
Arg34Thr 1 (1.1) 6 (3.2)
Ala36Pro 1 (1.1) 6 (3.2)
Ser50Arg 2 (2.3) 4 (2.2)
Gly47Arg 2 (2.3) 3 (1.6)
Glu54Lys 1 (1.1) 3 (1.6)
Val122Ile 3 (3.5) 3 (1.6)
Ser23Asn 2 (2.3) 2 (1.2)
Gly47Glu 1 (1.1) 2 (1.2)
Phe33Val 1 (1.1) 1 (0.5)
Hys88Arg 1 (1.1) 1 (0.5)
Val30Ala 1 (1.1) 1 (0.5)
Val14Leu 1 (1.1) 1 (0.5)
Gly53Ala 1 (1.1) 1 (0.5)
Gly57Arg 1 (1.1) 1 (0.5)
Tyr78Phe 1 (1.1) 1 (0.5)
Ile107Phe 1 (1.1) 1 (0.5)
Thr59Lys 1 (1.1) 1 (0.5)
Glu89Lys 1 (1.1) 1 (0.5)
Glu92Lys 1 (1.1) 1 (0.5)
Phe64Ile 1 (1.1) 1 (0.5)
Total 89 (100) 186 (100)
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Table 2 Patients’ main clinical characteristics at baseline according to phenotype classification
Overall Cardiac Mixed Neurologic Adjusted P-values
Patients, n 186 31 109 46 n.a.
Families, n 89 29 51 28 n.a.
Men, n (%) 130 (70) 29 (94)a,b 73 (67) 28 (61) 0.005*
Transthyretin mutationsc
Val30Met 46 (24.8) 0 (0)a,b 30 (27.5) 16 (34.8) 0.001*
Glu89Gln 40 (21.5) 1 (3.2)a 31 (28.5) 8 (17.4) 0.008*
Ile68Leu 27 (14.6) 23 (74.3)a,b 1 (0.9) 3 (6.5) ,0.001*
Phe64Leu 13 (7) 0 (0) 7 (6.4) 6 (13.1) 0.091
Thr49Ala 12 (6.5) 0 (0) 10 (9.2) 2 (4.3) 0.191
Gly47Ala 7 (3.8) 0 (0) 4 (3.7) 3 (6.5) n.a.
Arg34Thr 6 (3.2) 0 (0) 3 (2.8) 3 (6.5)
Ala36Pro 6 (3.2) 0 (0) 4 (3.7) 2 (4.3)
Ser50Arg 4 (2.2) 0 (0) 3 (2.8) 1 (2.2)
Glu54Lys 3 (1.6) 0 (0) 3 (2.8) 0 (0)
Gly47Arg 3 (1.6) 0 (0) 2 (1.8) 1 (2.2)
Val122Ile 3 (1.6) 2 (6.5) 0 (0) 1 (2.2)
Ser23Asn 2 (1.2) 1 (3.2) 1 (0.9) 0 (0)
Gly47Glu 2 (1.2) 0 (0) 2 (1.8) 0 (0)
Val14Leu 1 (0.5) 1 (3.2) 0 (0) 0 (0)
Hys88Arg 1 (0.5) 1 (3.2) 0 (0) 0 (0)
Tyr78Phe 1 (0.5) 1 (3.2) 0 (0) 0 (0)
Gly57Arg 1 (0.5) 0 (0) 1 (0.9) 0 (0)
Glu89Lys 1 (0.5) 1 (3.2) 0 (0) 0 (0)
Phe33Val 1 (0.5) 0 (0) 1 (0.9) 0 (0)
Val30Ala 1 (0.5) 0 (0) 1 (0.9) 0 (0)
Thr59Lys 1 (0.5) 0 (0) 1 (0.9) 0 (0)
Ile107Phe 1 (0.5) 0 (0) 1 (0.9) 0 (0)
Gly53Ala 1 (0.5) 0 (0) 1 (0.9) 0 (0)
Glu92Lys 1 (0.5) 0 (0) 1 (0.9) 0 (0)
Phe64Ile 1 (0.5) 0 (0) 1 (0.9) 0 (0)
Age at diagnosis, years [median (IQR)] 54 (41–66) 70 (62–75)a,b 53 (43–62) 42 (37–61) ,0.001*
Age at onset of symptoms, years [median (IQR)] 51 (39–63) 67 (60–73)a,b 50 (40–59) 41 (33–58) ,0.001*
Diagnostic route, n (%)
Neurologic 89 (47.8) 0 (0) 68 (62.4) 21 (45.7) ,0.001*,a,b,d
Cardiac 38 (20.4) 30 (96.8) 8 (7.3) 0 (0)
Family screening 59 (31.8) 1 (3.2) 33 (30.3) 25 (54.3)
Neurosensory involvement, n (%)
0 31 (16.7) 31 (100) 0 (0) 0 (0) n.a.
1 78 (41.9) 0 (0) 44 (43.6) 34 (63)
2 66 (35.4) 0 (0) 50 (49.5) 16 (29.6)
3 11 (6) 0 (0) 7 (6.9) 4 (7.4)
Autonomic involvement, n (%)
Orthostatic hypotension 55 (29.6) 0 (0) 42 (38.5) 13 (28.2) n.a.
Urinary incontinence 42 (22.6) 0 (0) 32 (29.4) 10 (21.7)
Gastrointestinal symptoms 79 (42.5) 0 (0) 61 (56) 18 (39.1)
NYHA class III– IV, n (%) 24 (12.9) 13 (41.9) 11 (10) 0 (0) n.a.
Vitreal involvement, n (%) 13 (6.9) 1 (3.2) 10 (9.2) 2 (4.3) 0.514
Carpal tunnel syndrome, n (%) 65 (34.9) 14 (45)b 45 (41.3)d 6 (13.1) 0.001*
n.a., not applicable.
*P-values were adjusted according to the Bonferroni method.
aP, 0.05 at post hoc analysis: cardiac vs. mixed.
bP, 0.05 at post hoc analysis: cardiac vs. neurologic.
cStatistical analysis on the distribution of different mutations between the different phenotypes regards only those mutations with at least 10 cases.
dP, 0.05 at post hoc analysis: mixed vs. neurologic.
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Although a single TTR mutation was responsible for .70% of
these cases, the remaining cases showed a high genotypic hetero-
geneity. Although ATTR with a cardiac phenotype is frequently
misdiagnosed as sarcomeric HCM, the disease profile is quite
specific and could allow a non-invasive clinical and instrumental
differential diagnosis.
The study population derives from three centres that collect a
relevant percentage of Italian ATTR patients through a wide spec-
trum of referral routes (neurological, cardiac, nephrological, haem-
atological, etc.). The relatively low prevalence of the Val30Met
mutation and the wide variety of other mutations (n ¼ 25) in
our cohort likely reflect a geographical scenario with a highly het-
erogeneous pool of genes due to historical reasons.
As expected, the characteristics of our patients were quite dif-
ferent from those of endemic early-onset Val30Met populations
from northern Portugal, Brazil, and Japan, in whom neurologic
phenotype is predominant, cardiac involvement is mainly limited
to conduction disturbances, and disease onset generally occurs
in the third–fourth decade of life.2 –5 In our population—as in
other series of ATTR Val30Met patients including France,
Sweden, and Japan2,3,5,24—disease onset tended to be relatively
late (often during the fifth decade), frequently affecting males
with overt heart involvement already at presentation.
Phenotypic heterogeneity and genotype–
phenotype correlations
Systematic evaluation of the neurologic/cardiac phenotype in this
extensive series of ATTR patients highlights the complexity of
the relationship between the two main clinical expressions of
this systemic disease. Although the vast majority (.80%) of the
affected patients showed neurological involvement, cardiac
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Clinical and electrocardiographic findings of patients with hereditary transthyretin-related amyloidosis, senile
systemic amyloidosis, and hypertrophic cardiomyopathy
ATTR with cardiac
phenotype (n 5 31)
Senile systemic
amyloidosis (n 5 30)
Hypertrophic
cardiomyopathy (n 5 30)
Adjusted
P-values
Age, years [median (IQR)] 67 (60–73)a 77 (72–80)b 64 (61–67) ,0.001*
Men, n (%) 29 (94) 28 (93) 26 (87) 0.65
Atrial fibrillation, n (%) 9 (29) 11 (37)b 2 (7) 0.02*
Pacemaker, n (%) 4 (13) 11 (37) 5 (17) 0.056
First-degree AV block, n (%) 4 (13) 9 (30) 6 (20) 0.243
Total QRS score, mV [median (IQR)] 123 (99–144)c 122 (110–155)b 155 (105–170) 0.023*
Low QRS voltage, n (%) 11 (35)c 10 (33)b 2 (7) 0.016*
Voltage/mass ratio [median (IQR)] 0.9 (0.5–1.3) 0.9 (0.5–1.4) 1.1 (0.8–1.7) 0.398
Right bundle branch block, n (%) 6 (19) 6 (20) 4 (13) 0.755
Left bundle branch block, n (%) 3 (10) 9 (30)b 2 (7) 0.03*
Left anterior hemiblock, n (%) 12 (39) 7 (23) 6 (20) 0.216
LV hypertrophy on ECG, n (%) 2 (7)c 3 (10)b 17 (57) ,0.001*
Presence of any infarct pattern, n (%) 17 (55) 10 (33) 11 (37) 0.185
‘Ischaemic pattern’ (negative T-waves), n/N (%) 17 (55)c 15 (50)b 24 (80) 0.037*
QTc interval, ms [median (IQR)] 486 (468–519)c 472 (433–499) 450 (429–469) 0.01*
Normal ECG, n (%) 0 (0) 0 (0) 2 (7) 0.125
IQR, interquartile range.
*P-values were adjusted according to the Bonferroni method.
aP, 0.05 at post hoc analysis: ATTR vs. SSA.
bP, 0.05 at post hoc analysis: SSA vs. HCM.
cP, 0.05 at post hoc analysis: ATTR vs. HCM.
Figure 1 Cumulative age-related incidence of symptoms
according to phenotype at presentation. Cases with senile sys-
temic amyloidosis are also shown for comparison. At 50 years
of age, ,10% of the patients with a cardiac phenotype and
none of the senile systemic amyloidosis patients have developed
disease manifestations, whereas nearly 50 and 70% of the patients
with a mixed and a neurologic phenotype, respectively, already
show symptoms. More than 50% of the patients with senile sys-
temic amyloidosis manifest the disease after 75 years of age,
whereas all hereditary transthyretin-related amyloidosis patients
with a neurologic or a mixed phenotype and most of those
with a cardiac phenotype have already developed symptoms.
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manifestations were remarkably common. As many as two-thirds
of the patients had some clinical or instrumental signs of cardiac
involvement, and a relevant minority (15%) had an exclusively
cardiac phenotype. For the purpose of phenotypic classification,
we did not consider carpal tunnel syndrome as a specific sign of
ATTR neurological involvement, since it is a common finding in
the general population.25 Although a single TTR mutation
(Ile68Leu) accounted for the majority of patients with this pheno-
type, seven other mutations were also responsible for this presen-
tation in our Italian patient population. This genotypic
heterogeneity among our Caucasian patients with cardiac pheno-
type is peculiar when compared with the close relationship
between single TTR mutations and cardiac phenotype found
among US African-Americans (Val122Ile),7,26 patients from the
Appalachian and Irish Donegal regions (Thr60Ala),8,27 and
Denmark (Leu111Met).9 Our findings reinforce the concept of a
spectrum of genotype–phenotype correlations that ranges from
largely ‘neurologic’ mutations (e.g. Val30Met) to purely ‘cardiac’
ones (e.g. Ile68Leu and Val122Ile) through mutations associated
with variable, mixed phenotypes (Figure 2).1 –3,5,8,10,18,28– 30
The molecular basis of tissue specificity of individual TTR
variants—which was outside the scope of this paper—is still
largely unknown. There is no established relationship between
any structural feature of the different TTR mutations and the se-
lective amyloid deposits in cardiac, nervous, or leptomeningeal
tissues.31 However, it has been hypothesized that several
factors such as protein stability, proteolytic remodelling by
tissue-specific proteases, and/or interaction with extracellular
components, including matrix molecules and chaperones, might
be involved.31– 33 Moreover, even though the overall degree of
genotype–phenotype correlation is high, a single gene mutation
does not necessarily lead to the expression of a single phenotype
and a relevant intra-mutation and intra-familial heterogeneity was
apparent (Table 2).
Disease profile of patients with a cardiac
phenotype and differential diagnosis
The clinical and instrumental profile of ATTR with a cardiac pheno-
type is relatively well defined. In fact, nearly all cases are men aged
.65, with heart failure symptoms, symmetric LV ‘hypertrophy’
without LV dilatation, and with moderately depressed LV ejection
fraction on echocardiogram. Age at diagnosis [70 (62–75) years]
is on average 17 years older compared with patients with a
mixed phenotype [53 (43–62) years] and 28 years higher
compared with patients with a neurologic phenotype [42 (37–
61) years] (Figure 1). These intriguing differences can only partially
be attributed to the differences of age-related penetrance of the
different mutations, since cardiac manifestations occur at an
older age compared with neurological ones even among patients
who share the same mutation. The explanation of this phenom-
enon is not clear. On the one hand, it is possible that the
absence of neurological symptoms causes the patient to seek
medical attention later. On the other, however, it is highly plausible
that myocardial infiltration in ATTR (both wild-type and heredi-
tary) requires longer than the time required to develop axonal
neuropathy.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Echocardiographic findings of patients with hereditary transthyretin-related amyloidosis, senile systemic
amyloidosis, and hypertrophic cardiomyopathy
ATTR with cardiac
phenotype (n5 31)
Senile systemic
amyloidosis (n5 30)
Hypertrophic
cardiomyopathy (n 5 30)
Adjusted
P-values
Diastolic interventricular septum thickness, mm
[median (IQR)]
18 (16–20) 18 (16–22) 19 (17–22) 0.23
Diastolic LV posterior wall thickness, mm [median (IQR)] 16 (15–18)a 17 (14–19)b 14 (13–15) ,0.002*
Maximal LV wall thickness
.12 mm, n (%) 31 (100) 30 (100) 30 (100) n.a.
.14 mm, n (%) 27 (87) 25 (83) 26 (87) 0.93
Symmetric LV hypertrophy, n (%) 30 (97)a 29 (97)b 15 (50) 0.007*
Indexed LV mass among men, g/m2 [median (IQR)]* 225 (193–261)a 247 (204–288)b 186 (176–200) 0.004*
Left atrial diameter, mm [median (IQR)] 47 (44–51) 51 (44–56) 51 (43–53) 0.302
LV ejection fraction, % [median (IQR)] 45 (36–51)a 50 (35–58)b 68 (67–76) ,0.001*
LV end-diastolic diameter, mm [median (IQR)] 49 (48–51)a 47 (43–50) 44 (40–47) 0.002*
E-wave deceleration time, ms [median (IQR)] 160 (135–175)a 159 (125–180)b 185 (180–215) 0.005*
Restrictive filling pattern, n (%) 12 (39) 9 (30) 4 (13) 0.079
Pericardial effusion, n (%) 17 (55)a 13 (43)b 1 (3) ,0.001*
Atrioventricular valve thickening, n (%) 19 (61)a 15 (50)b 1 (3) ,0.001*
n.a., not applicable; IQR, interquartile range.
*P-values were adjusted according to the Bonferroni method.
aP, 0.05 at post hoc analysis: ATTR vs. HCM.
bP, 0.05 at post hoc analysis: SSA vs. HCM.
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Our finding that most patients with cardiomyopathy were men
is in line with the hypothesis that female gender may confer some
degree of protection against myocardial amyloid deposition.34
Compared with patients with a mixed phenotype, patients with
a cardiac phenotype have a more pronounced cardiac involvement
as shown by both echocardiogram and ECG (Supplementary ma-
terial online). Once again, it is difficult to establish whether these
differences are due to a lead-time bias or, more probably, the
degree of myocardial infiltration is intrinsically greater in some
TTR mutations and in some ATTR patients.
When reviewing the literature, only few reports regarding ATTR
patients with a cardiac phenotype are available and are mainly
derived from cohorts of patients with single TTR mutations.7– 9
In the only two papers that report detailed echocardiographic
data from a small number of patients with the Val122Ile mutation,
both interventricular septum thickness and LV ejection fraction
values are comparable with our findings.26,35 Similarly, cardiac in-
volvement of Irish and Scottish patients with Thr60Ala mutation
is characterized by symmetric LV hypertrophy and moderate LV
systolic dysfunction, in the absence of low QRS voltages in the
vast majority of cases.8
Our data confirm that ATTR with an exclusively cardiac pheno-
type is frequently mistaken for HCM. The availability of an age- and
gender-matched control group with genetically proven sarcomeric
HCM allowed us to compare different types of cardiomyopathies
with LV hypertrophy. Indeed, a careful interpretation of ECG
and echocardiogram may offer many useful hints for a differential
diagnosis. On echocardiogram, the major differences involve
hypertrophy distribution (symmetric in ATTR and generally asym-
metric in HCM), the LV systolic function (greater LV end-diastolic
dimension and lower LV ejection fraction in amyloidotic cardiomy-
opathy), and the coexistence of pericardial effusion and increased
atrioventricular valve thickness (frequent in patients with
amyloidotic cardiomyopathy and almost absent in HCM).
On ECG, the main differences regard the frequency of ‘ischae-
mic’ abnormalities (much more frequent in HCM), the QTc inter-
val (longer in amyloidotic cardiomyopathy), and low QRS voltages
(higher prevalence in ATTR and SSA). Nevertheless, despite a
significant difference in the average QRS score values between
the two groups, only 35% of the patients with ATTR showed a
low QRS voltage pattern. This finding confirms previous observa-
tions reporting a high prevalence of low QRS voltages only in
AL-related cardiac amyloidosis.17,36
While an accurate study of the echocardiographic and ECG find-
ings can direct towards the right diagnosis between TTR-related
cardiomyopathies and HCM, the differential diagnosis between
ATTR and SSA is based solely on molecular genetics. Indeed,
excluding age, no other clinical or instrumental finding differed
significantly between the two groups.
Therapeutic implications
Peculiar therapeutic problems arise when considering ATTR
patients with an exclusively cardiac phenotype. In ATTR, orthoto-
pic liver transplantation (OLT) has proven to be effective in halting
the progression of neurological amyloid disease and currently
represents the only available disease-modifying treatment.37
Figure 2 Possible spectrum of genotype–phenotype correlations in transthyretin-related amyloidosis. Phenotypic expression of
transthyretin-related amyloidosis varies widely from an almost exclusively neurological involvement (Val30Met mutation with early-onset
disease) to a predominant or exclusively cardiac involvement (Thr60Ala, Leu111Met, Ile68Leu, and Val122Ile mutations). In between,
several transthyretin-related amyloidosis mutations are associated with variable degrees of neurological and cardiological involvement, including
Val30Met with late-onset disease.
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However, even after a successful OLT, a relevant number of
patients with cardiac involvement show a cardiomyopathy progres-
sion.38 In ATTR patients with an exclusively cardiac phenotype
who face heart disease progression but not the development of
neurological symptoms, OLT could be questionable. Our decision
to submit four of our patients to combined heart– liver transplant-
ation ensued from the need for heart replacement, while also fol-
lowing the current (even though generic) indications for OLT in
ATTR amyloidosis. However, in patients with an exclusively
cardiac phenotype, the absence of neurological manifestation
could be the rationale to perform isolated heart transplantation.
This strategy has already been applied in single patients with
Ile122Val mutation and symptomatic amyloidotic cardiomyop-
athy.39 Further larger studies would contribute to better direct
therapeutic choices. Moreover, patients with a cardiac phenotype
should be included in dedicated prospective protocols that inves-
tigate the effects of new TTR stabilizers (diflunisal and tafamidis)
on disease progression.40,41
Limitations
Our study essentially provides information on the phenotypic het-
erogeneity of ATTR at presentation. The possible phenotypic evo-
lution during the natural history of the disease has been only
partially captured by our study design. Our data on the prevalence
of different phenotypes may not necessarily apply to other geo-
graphical areas with different genetic backgrounds. Nevertheless,
given the analogies between echocardiographic and ECG profiles
of our patients with cardiac phenotype and those previously
reported for patients carrying the Val122Ile or Thr60Ala muta-
tions, it is plausible that our hints for differential diagnosis
between ATTR and HCM could also be useful in other contexts.
In this regard, despite the consistent statistical differences of
many clinical and instrumental variables between TTR-related car-
diomyopathy and HCM, the limited size of the subgroups did not
allow us to obtain reliable specificity and sensitivity values.
Conclusions
A clinically relevant subset (15%) of Caucasian ATTR patients
from non-endemic areas has an exclusively cardiac phenotype at
presentation and does not develop relevant neurological symp-
toms at a mid-term follow-up. This amyloidotic cardiomyop-
athy—which is associated with several TTR mutations—is
frequently mistaken for HCM or SSA. While an accurate study
of the echocardiographic and ECG findings can direct towards
the right diagnosis between TTR-related cardiomyopathies and
HCM, the differential diagnosis between ATTR and SSA is based
solely on molecular genetics.
In patients with an exclusively cardiac phenotype, the role of
liver transplantation should be reconsidered, since the absence
of neurological manifestation may be the rationale to perform
isolated heart transplantation.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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